- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock | 4 | Investing.com | ||
| Di | Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating | 1 | Investing.com | ||
| Di | H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns | 1 | Investing.com | ||
| Mo | Aktie von Lexeo Therapeutics bricht nach Studiendaten zur Gentherapie ein | 5 | Investing.com Deutsch | ||
| Mo | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mo | Lexeo: Positive Studiendaten zu Gentherapie bei Herzerkrankung | 3 | Investing.com Deutsch | ||
| Mo | Lexeo's gene therapy shows promising results for heart condition | 3 | Investing.com | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy | 78 | GlobeNewswire (Europe) | LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants... ► Artikel lesen | |
| 08.01. | Lexeo Therapeutics Partners With JNJ To Investigate Localized Cardiac Delivery Of Gene Therapy | 306 | AFX News | NEW BRUNSWICK (dpa-AFX) - Lexeo Therapeutics, Inc. (LXEO), Thursday announced a research collaboration with Johnson & Johnson (JNJ) to investigate localized cardiac delivery of gene therapy.Under... ► Artikel lesen | |
| 08.01. | Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy | 98 | GlobeNewswire (Europe) | Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson's expertise in cardiovascular therapeutics and circulatory technologies, including Impella heart pumps... ► Artikel lesen | |
| 27.12.25 | Wall Street Rallies Behind Lexeo Therapeutics (LXEO)'s Gene Therapy Pipeline | 3 | Insider Monkey | ||
| 17.12.25 | Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating | 3 | Investing.com | ||
| 10.12.25 | Lexeo Therapeutics stock holds Overweight rating as Cantor sees PKP2-ACM potential | 1 | Investing.com | ||
| 10.12.25 | Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock | 1 | Investing.com | ||
| 01.12.25 | Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target | 2 | Investing.com | ||
| 01.12.25 | Cantor Fitzgerald stuft Lexeo Therapeutics als unterbewertet ein und bestätigt Kursziel von 19 $ | 1 | Investing.com Deutsch | ||
| 05.11.25 | Lexeo Therapeutics GAAP EPS of -$0.33 beats by $0.24 | 3 | Seeking Alpha | ||
| 05.11.25 | Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights | 309 | GlobeNewswire (Europe) | FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved... ► Artikel lesen | |
| 05.11.25 | Lexeo Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.11.25 | Lexeo Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,352 | +0,26 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices Appoints Rich McAvoy as Chief Business Officer | Seasoned business and finance leader brings disciplined growth mindset to support Avid's next phase of expansion and client executionTUSTIN, Calif., Jan. 15, 2026 /PRNewswire/ -- Avid Bioservices... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,800 | +2,27 % | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
/ Key word(s): Agreement
Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement
17.12.2025... ► Artikel lesen | |
| REPLIMUNE | 6,100 | +0,83 % | Replimune Group, Inc. - 8-K, Current Report | ||
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| QUANTERIX | 7,400 | -6,92 % | Quanterix Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| BELITE BIO | 132,00 | +3,12 % | Cantor Fitzgerald reiterates Overweight rating on Belite Bio stock | ||
| PRAXIS PRECISION MEDICINES | 317,25 | +6,55 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,51 | -0,12 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,14 | -3,41 % | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 88,64 | +4,26 % | Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why | ||
| QIAGEN | 40,990 | +0,42 % | QIAGEN - hält was es verspricht | Das Unternehmen aus Hilden hat seine Prognosen im abgelaufenen Geschäftsjahr erreicht. Nun geht es optimistisch in das neue Jahr, in dem es sich auf die Förderung der Produktvermarktung, regulatorische... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,310 | -1,09 % | ADMA Biologics, Inc. (ADMA): A Bull Case Theory | ||
| BEAM THERAPEUTICS | 31,220 | -2,59 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| ERASCA | 9,625 | +0,68 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen |
LEXEO THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,110 (-1,47 %) liegt der Kurs bei 7,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.